CasNo.141732-76-5,Exenatide acetate 141732-76-5 supplier,(141732-76-5) Suppliers

1 Milligram	FOB Price: USD 1.0000

Min.Order :1 Milligram
Purity: 98%
Payment Terms : L/C,T/T,Other

Keywords

Exenatide acetate 141732-76-5 high purity Exenatide acetate 141732-76-5 Exenatide acetate 141732-76-5 supplier in China

Quick Details

Appearance:white powder
Application:Exenatide (i, INN, marketed as Byetta, Bydureon) is a glucagon-like peptide-1 agonist (GLP-1 agonist) medication, belonging to the group of incretin mimetics, approved in April 2005 for the treatment
PackAge:Aluminum foil bag/bottle
ProductionCapacity:100|Metric Ton|Year
Storage:2~8℃
Transportation:According your requirement

Superiority:

Nanjing Sunsure Chemical Technology Co., Ltd., established in 2009, has expanded a compositive entity from initially only as a small manufacturer. The company dedicated to the development, production and marketing of chemicals. Sunsure covers whole range from small amount (gram grade) for research to big bulk for industrial production. Synthesis capacity from 1 liter to 3000 liter is available.

Sunsure Chemical focus on:

-Organic compounds

-Active Pharmaceutical Ingredient(s)

-Nutritional products

-Custom synthesis

-Contract Manufacturing

Details:

Nanjing Sunsure Chemical Technology Co., Ltd., established in 2009, has expanded a compositive entity from initially only as a small manufacturer. The company dedicated to the development, production and marketing of chemicals. Sunsure covers whole range from small amount (gram grade) for research to big bulk for industrial production. Synthesis capacity from 1 liter to 3000 liter is available.

Sunsure Chemical focus on:

-Organic compounds

-Active Pharmaceutical Ingredient(s)

-Nutritional products

-Custom synthesis

-Contract Manufacturing

Exenatide (i, INN, marketed as Byetta, Bydureon) is a glucagon-like peptide-1 agonist (GLP-1 agonist) medication, belonging to the group of incretin mimetics, approved in April 2005 for the treatment of diabetes mellitus type 2. Exenatide in its Byetta form is administered as a subcutaneous injection (under the skin) of the abdomen, thigh, or arm, any time within the 60 minutes before the first and last meal of the day. A once-weekly injection has been approved as of January 27, 2012 under the trademark Bydureon. It is manufactured by Amylin Pharmaceuticals and commercialized by AstraZeneca.